Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MLYCD | O95822 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272675 | 0.84 | HSD17B10 (0.60) | HSD17B10USP2MEN1KMT2AMLYCD | |
| SCHEMBL23818000 | 0.84 | ALDH1A1 (0.72) | HSD17B10USP2MEN1KMT2AMLYCD | |
| SCHEMBL11422402 | 0.83 | HSD17B10 (0.67) | HSD17B10USP2MEN1KMT2AMLYCD | |
| SCHEMBL6633322 | 0.80 | HSD17B10 (0.63) | HSD17B10USP2MEN1KMT2AMLYCD | |
| SCHEMBL11140198 | 0.80 | HSD17B10 (0.63) | HSD17B10USP2MEN1KMT2AMLYCD | |
| SCHEMBL17438744 | 0.80 | HSD17B10 (0.63) | HSD17B10USP2MEN1KMT2AMLYCD | |
| SCHEMBL6633325 | 0.80 | HSD17B10 (0.63) | HSD17B10USP2MEN1KMT2AMLYCD | |
| SCHEMBL27528022 | 0.80 | HDAC3 (0.54) | MEN1KMT2AALDH1A1HTTRAB9A | |
| SCHEMBL28734160 | 0.77 | HSD17B10 (0.55) | HSD17B10USP2MEN1KMT2AMLYCD | |
| SCHEMBL11879274 | 0.76 | HSD17B10 (0.58) | HSD17B10USP2MEN1KMT2AMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| EP-1317459-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020530-A1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | HSD17B10 1713/4885USP2 4751/4885MEN1 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.